Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Topics
  4. Diseases and Illnesses
  5. Covid-19

Covid-19

Thumbnail
May 16, 2022

Valneva and Synairgen remain Covid laggards

Thumbnail
May 09, 2022

Covid drives a record jump in research spending for big pharma

A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.

Thumbnail
May 16, 2022

Valneva and Synairgen remain Covid laggards

Thumbnail
May 09, 2022

Covid drives a record jump in research spending for big pharma

A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.

Article image
Vantage logo
April 27, 2022

A bad day for Molecular Partners

Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.

Article image
Vantage logo
April 20, 2022

First-quarter biotech risers work hard for the win

Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.

Article image
Vantage logo
April 20, 2022

Arcturus’s latecomer Covid vaccine elicits little interest

Article image
Vantage logo
April 19, 2022

Outside big pharma, life remains tough for listed developers

A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.

Article image
Vantage logo
April 12, 2022

Veru gets a big Covid boost

But full data will be needed to confirm that sabizabulin is a real contender.

Article image
Vantage logo
March 30, 2022

Adagio gets a second chance

Article image
Vantage logo
March 25, 2022

Moderna needs to dispel doubts about its post-Covid strategy

Article image
Vantage logo
March 04, 2022

UK Recovery trial confirms Covid benefit for Olumiant

But, in the US, the NIH-backed Activ-2 trial shuts down an arm studying an SAB antibody, and tells Synairgen to hold tight.

Article image
Vantage logo
March 02, 2022

Rare disease and neurology takeouts tick higher

Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Article image
Vantage logo
April 27, 2022

A bad day for Molecular Partners

Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.

Article image
Vantage logo
April 20, 2022

First-quarter biotech risers work hard for the win

Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.

Article image
Vantage logo
April 20, 2022

Arcturus’s latecomer Covid vaccine elicits little interest

Article image
Vantage logo
April 19, 2022

Outside big pharma, life remains tough for listed developers

A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.

Article image
Vantage logo
April 12, 2022

Veru gets a big Covid boost

But full data will be needed to confirm that sabizabulin is a real contender.

Article image
Vantage logo
March 30, 2022

Adagio gets a second chance

Article image
Vantage logo
March 25, 2022

Moderna needs to dispel doubts about its post-Covid strategy

Article image
Vantage logo
March 04, 2022

UK Recovery trial confirms Covid benefit for Olumiant

But, in the US, the NIH-backed Activ-2 trial shuts down an arm studying an SAB antibody, and tells Synairgen to hold tight.

Article image
Vantage logo
March 02, 2022

Rare disease and neurology takeouts tick higher

Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.